Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tumor Microenvironment
100%
Cancer Patients
33%
Tumor
33%
Tumor Immunity
30%
Clinical Trial Design
24%
Human Cancer
24%
B7 Family
24%
Immune Evasion
24%
Cancer Immunotherapy
24%
Immune Escape
24%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
18%
Immune Checkpoint
18%
Programmed Death-ligand 1 (PD-L1)
18%
HHLA2
18%
Aberrant Expression
15%
Clinical Data
15%
T Cell Activation
15%
Escape Mechanism
15%
Tumor Growth
15%
Murine Tumor Model
15%
Clinical Research
15%
Functional Consequences
15%
Disease Progression
15%
Co-inhibition
15%
Multidisciplinary Team
15%
Poor Clinical Outcomes
15%
In Cancer
15%
Host Cell
15%
Specific Intent
15%
Tumor Progression
15%
Complementary Skills
15%
Immune Checkpoint Blockade
11%
Checkpoint Blockade
10%
Crystal Structure Analysis
10%
Granted Patents
10%
Molecular Mechanism
9%
New Humanities
9%
Combination Therapy
9%
Immunosuppression
9%
Cancer Treatment
9%
Cellular Mechanisms
9%
Targeted Therapy
9%
Therapeutic Target
9%
Human Immune System
9%
Anti-CTLA-4 Therapy
6%
Medicine and Dentistry
Tumor Microenvironment
93%
Immune Evasion
48%
Neoplasm
40%
Malignant Neoplasm
31%
Tumor Progression
30%
Tumor Immunity
30%
Immunotherapy
28%
CTLA-4
25%
Programmed Death-Ligand 1
19%
Host Cell
15%
Tumor Model
15%
Disease Exacerbation
15%
Clinical Research
15%
Cancer Immunotherapy
15%
T Cell
15%
Immune Checkpoint Blockade
11%
Combination Therapy
11%
Cancer Treatment
10%
Immunosuppressive Treatment
9%
Clinical Study
9%
Structure Analysis
9%
Targeted Therapy
9%
Cellular Mechanism
9%
Immunity
6%
Immunology and Microbiology
Immune Evasion
93%
Tumor Immunity
50%
Immunotherapy
46%
CTLA-4
43%
Programmed Death-Ligand 1
43%
Immune Checkpoint Blockade
26%
Murine
25%
T Cell
25%
Host Cell
25%
Cancer Immunotherapy
25%
Crystal Structure
21%
Immunosuppression
21%
Immunity
12%